Robert Zamboni - NeuBase Therapeutics Chief Board

NBSEDelisted Stock  USD 1.62  0.17  9.50%   

Insider

Robert Zamboni is Chief Board of NeuBase Therapeutics
Phone412 763 3350
Webhttps://www.neubasetherapeutics.com

NeuBase Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.4303) % which means that it has lost $0.4303 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9346) %, meaning that it created substantial loss on money invested by shareholders. NeuBase Therapeutics' management efficiency ratios could be used to measure how well NeuBase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
NeuBase Therapeutics currently holds 6 M in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. NeuBase Therapeutics has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about NeuBase Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

MBA MDCullinan Oncology LLC
51
Waldemar PriebeCns Pharmaceuticals
N/A
Assaf OronBiomx Inc
50
Susan KalledCompass Therapeutics
61
Merav BassanBiomx Inc
58
John CastleMonte Rosa Therapeutics
53
Irena KonstantinovaInventiva Sa
N/A
FESC MDNewAmsterdam Pharma
68
John CiniSonnet Biotherapeutics Holdings
71
Michael CooremanInventiva Sa
66
Jacquelyn JDCullinan Oncology LLC
46
Peter MoestaCompass Therapeutics
N/A
LaBella MSZyVersa Therapeutics
66
Jonathan MBABiomx Inc
47
DSc MSEImmix Biopharma
75
Inbar GahaliSassBiomx Inc
N/A
Corinne SavillCullinan Oncology LLC
65
Jennifer MichaelsonCullinan Oncology LLC
57
Ajim CFAMonte Rosa Therapeutics
47
Karen CashmereZyVersa Therapeutics
72
Inbal BenjaminiElranBiomx Inc
N/A
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Neu Base operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. NeuBase Therapeutics (NBSE) is traded on NASDAQ Exchange in USA and employs 37 people.

Management Performance

NeuBase Therapeutics Leadership Team

Elected by the shareholders, the NeuBase Therapeutics' board of directors comprises two types of representatives: NeuBase Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuBase. The board's role is to monitor NeuBase Therapeutics' management team and ensure that shareholders' interests are well served. NeuBase Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuBase Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Todd Branning, CFO Secretary
Dietrich Stephan, President CEO, Director
Curt Bradshaw, Chief Officer
Robert Zamboni, Chief Board
Alan JD, G Counsel
Ron MBA, Sr Devel
Shannon McCarthy, Chief Officer

NeuBase Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NeuBase Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Consideration for investing in NeuBase Stock

If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Global Correlations
Find global opportunities by holding instruments from different markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Fundamental Analysis
View fundamental data based on most recent published financial statements
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Share Portfolio
Track or share privately all of your investments from the convenience of any device